Pleospora Herbarum

Dosage for Pleospora Herbarum is highly individualized and must be determined by a specialist based on the patient's sensitivity level. There is no 'standard' dose for all patients.

Diagnostic Dosing

• Scratch/Prick/Puncture Test: Usually performed using a 1:10 or 1:20 w/v glycerinated extract. A single drop is applied to the skin, and the skin is pricked. A positive reaction is a wheal ≥3mm larger than the negative control.
• Intradermal Test: If the prick test is negative, an intradermal injection of 0.02 mL to 0.05 mL of a much more dilute aqueous extract (e.g., 1:1,000 w/v) may be administered.

Immunotherapy Dosing (SCIT)

• Build-up Phase: Injections are typically given 1 to 2 times per week. The starting dose is usually 0.1 mL of a very dilute solution (e.g., 1:100,000 w/v). The dose is increased by 50% to 100% at each visit until the maintenance dose is reached.
• Maintenance Phase: Once the maximum tolerated dose is achieved (the 'maintenance dose'), the interval between injections is increased to every 2 to 4 weeks. A common maintenance volume is 0.5 mL of a 1:100 w/v or 1:10 w/v solution, depending on patient tolerance.

Pleospora Herbarum is used in children, but the dosage must be approached with extreme caution. Children are generally started at the same dilutions as adults, but the increments during the build-up phase may be smaller to minimize the risk of systemic reactions. Clinical studies have shown that immunotherapy is generally effective in children aged 5 and older. Use in children under age 5 is generally avoided unless the allergic burden is severe and other treatments have failed.

Renal Impairment

No specific dosage adjustments are required for patients with renal impairment, as the extract is not cleared via traditional renal filtration of active drug molecules. However, the patient's overall health should be stable before administration.

Hepatic Impairment

No dosage adjustments are necessary for hepatic impairment. The metabolic breakdown of allergenic proteins is not dependent on hepatic CYP450 function.

Elderly Patients

Elderly patients may have a higher prevalence of underlying cardiovascular disease. Because epinephrine (the treatment for a severe reaction) can be risky in patients with heart disease, the maintenance dose for Pleospora Herbarum may be kept lower in this population to ensure a higher safety margin.

• Administration: Pleospora Herbarum must only be administered by a healthcare professional prepared to treat anaphylaxis. It is given via subcutaneous injection, usually in the posterior aspect of the upper arm.
• Observation: Patients MUST remain in the medical office for at least 30 minutes following an injection. Most fatal reactions to allergenic extracts occur within this window.
• Storage: Vials must be stored in a refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze. If the extract becomes cloudy or changes color, it should be discarded.
• Site Rotation: Injection sites should be rotated between the left and right arms to prevent local tissue changes.

If a dose is missed during the build-up phase, the next dose may need to be reduced. If the lapse is longer than 7-10 days, the physician may repeat the previous dose. If the lapse is several weeks, the dose may need to be reduced by several levels to prevent a systemic reaction due to loss of tolerance.

An 'overdose' in the context of Pleospora Herbarum usually refers to an injection of a concentration higher than the patient's current tolerance level. Signs include immediate generalized itching, hives, swelling of the throat, wheezing, and drop in blood pressure. Emergency treatment with epinephrine is required immediately.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose or skip visits without medical guidance, as this increases the risk of a severe reaction.

Most patients receiving Pleospora Herbarum immunotherapy will experience some form of local reaction. These are generally not dangerous but can be uncomfortable.

• Local Redness (Erythema): A red patch at the injection site that may appear within minutes and last for several hours.
• Swelling (Wheal): A raised, firm bump at the injection site. If the swelling is larger than the size of a half-dollar (approx. 3-4 cm), it should be reported to the doctor before the next dose.
• Itching (Pruritus): Localized itching at the site of injection is very common and can often be managed with topical hydrocortisone or oral antihistamines.

• Delayed Local Reactions: Swelling and redness that appear 6 to 24 hours after the injection. These are typically treated with ice packs and NSAIDs.
• Fatigue: Some patients report feeling unusually tired for the remainder of the day following an injection.
• Mild Nasal Congestion: A slight increase in 'hay fever' symptoms shortly after the dose.

• Generalized Urticaria: Hives appearing on parts of the body far from the injection site.
• Angioedema: Swelling of the lips, eyelids, or extremities.
• Persistent Cough: A dry, hacking cough that may signal the beginning of a systemic respiratory reaction.

> Warning: Stop taking Pleospora Herbarum and call your doctor immediately or seek emergency care if you experience any of the following symptoms of anaphylaxis:

• Difficulty Breathing or Wheezing: Indicates bronchospasm or airway narrowing.
• Throat Tightness: A feeling that the throat is closing or difficulty swallowing.
• Rapid or Weak Pulse: Signs of cardiovascular compromise.
• Dizziness or Fainting: Indicates a dangerous drop in blood pressure (hypotension).
• Cyanosis: A bluish tint to the lips or fingernails, indicating lack of oxygen.
• Seizures: Extremely rare, associated with severe hypoxia during anaphylaxis.

There are no known long-term 'toxic' effects of Pleospora Herbarum on the liver, kidneys, or brain. The primary long-term consideration is the potential for 'immunological memory' changes. In rare cases, patients may develop a persistent sensitivity or, conversely, a complete resolution of symptoms that lasts for years after the therapy is discontinued.

According to FDA standards for all allergenic extracts, Pleospora Herbarum carries a significant warning regarding Anaphylaxis.

Summary of Warning:

• Pleospora Herbarum can cause severe, life-threatening systemic reactions, including anaphylaxis.
• It should only be administered in a setting where emergency equipment and trained personnel are available to treat such reactions.
• Patients with unstable or severe asthma are at a significantly higher risk for fatal reactions.
• Patients taking beta-blockers may be resistant to the effects of epinephrine used to treat a reaction.

Report any unusual symptoms, even if they seem minor, to your healthcare provider. Keeping a 'symptom diary' can help your allergist adjust your dose safely.

Pleospora Herbarum is a potent biological agent. Its use requires a careful balance between therapeutic benefit and the risk of induced allergic reactions. Patients must be fully informed that while the goal is to reduce allergy symptoms, the treatment itself involves injecting the very substance to which they are allergic.

No FDA black box warnings for Pleospora Herbarum are currently listed in the same format as pharmaceutical drugs (like antidepressants), but it is subject to the General Allergenic Extract Warning which is functionally equivalent. This warning emphasizes that:

1. 1Extreme caution is necessary when switching from one manufacturer's extract to another.
2. 2Injections should never be given intravenously.
3. 3Fatalities have occurred with allergenic extracts due to failure to observe the 30-minute waiting period.

• Allergic Reactions / Anaphylaxis Risk: This is the primary risk. Patients must be evaluated for 'high-risk' status, which includes those with highly positive skin tests or those who have had previous systemic reactions to other allergens.
• Asthma Status: Patients must have their asthma under control before receiving an injection. If a patient is experiencing an asthma flare-up or has a reduced Peak Flow reading that morning, the injection should be postponed.
• Infection/Fever: Injections should be deferred if the patient has an acute infection or fever, as the immune system is already stressed.
• Cardiovascular Disease: Patients with significant heart disease must be evaluated carefully, as they may not tolerate the physiological stress of a systemic reaction or the epinephrine required to treat it.

• 30-Minute Wait: Mandatory observation after every injection.
• Peak Flow Monitoring: For asthmatic patients, monitoring lung function before and after injections may be required.
• Skin Test Re-evaluation: Periodic re-testing (every 2-3 years) may be performed to assess the progress of the immunotherapy.

Generally, Pleospora Herbarum does not cause sedation. However, if a patient experiences a systemic reaction or receives epinephrine, they should not drive until cleared by a physician.

Alcohol should be avoided for several hours before and after an injection. Alcohol causes vasodilation (widening of blood vessels), which can increase the rate of allergen absorption from the injection site, potentially increasing the risk of a systemic reaction.

Immunotherapy is typically a 3- to 5-year commitment. Stopping abruptly does not cause 'withdrawal' in the pharmacological sense, but it may result in a rapid return of allergy symptoms. If the treatment is stopped for several months and then restarted, the patient must start back at the most dilute concentration to ensure safety.

> Important: Discuss all your medical conditions, especially respiratory or heart problems, with your healthcare provider before starting Pleospora Herbarum.

• Beta-Blockers (e.g., Propranolol, Atenolol, Metoprolol): These medications are generally contraindicated in patients receiving Pleospora Herbarum immunotherapy. Beta-blockers can make a systemic allergic reaction much more severe and, crucially, they can block the life-saving effects of epinephrine (adrenaline) if it needs to be administered during anaphylaxis.

• ACE Inhibitors (e.g., Lisinopril, Enalapril): Some studies suggest that patients on ACE inhibitors may be at an increased risk for more severe systemic reactions during immunotherapy, possibly due to the role of bradykinin.
• MAO Inhibitors (e.g., Phenelzine, Selegiline): These can potentiate the effects of epinephrine, leading to dangerously high blood pressure if an emergency injection is required.
• Tricyclic Antidepressants (e.g., Amitriptyline): Similar to MAOIs, these can increase the cardiovascular response to epinephrine.

• Antihistamines (e.g., Loratadine, Cetirizine, Diphenhydramine): These medications will interfere with the results of diagnostic skin testing. Patients must typically stop taking antihistamines for 3 to 7 days before a Pleospora Herbarum skin test. However, they are often continued during the immunotherapy phase to reduce local injection-site reactions.

There are no direct food-drug interactions with Pleospora Herbarum. However, patients with a 'mold-yeast' cross-sensitivity may find their symptoms exacerbated if they consume large amounts of fermented foods (cheeses, mushrooms, vinegar) on the day of their injection. This is not a formal drug interaction but a clinical observation in sensitive individuals.

• St. John’s Wort: While no direct interaction exists, St. John's Wort can affect the metabolism of many drugs. Its impact on the immune response to fungal extracts is unknown.
• Immune Stimulants (e.g., Echinacea): These may theoretically interfere with the 'desensitization' goal of immunotherapy, although clinical data is lacking.

• Skin Prick Tests: As mentioned, antihistamines and certain sleep aids (with antihistamine properties) will cause a false-negative result.
• Total IgE/Specific IgE (RAST/ImmunoCAP): Pleospora Herbarum immunotherapy will eventually cause a decrease in specific IgE levels and an increase in IgG4 levels, which is the intended clinical outcome and not an 'interference.'

For each major interaction, the mechanism is usually pharmacodynamic (affecting the body's response to the drug) rather than pharmacokinetic (affecting the drug's levels). The management strategy is always to perform a thorough medication reconciliation before the first dose.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, especially any 'heart' or 'blood pressure' pills.

Pleospora Herbarum must NEVER be used in the following circumstances:

• Severe, Uncontrolled Asthma: If a patient's FEV1 is consistently below 70% of predicted value, the risk of a fatal reaction to the extract is unacceptably high. The airway is already compromised, and any further constriction could be fatal.
• Recent Myocardial Infarction (Heart Attack): Within the last 3-6 months. The heart may not be able to withstand the stress of an anaphylactic event.
• History of Severe Reaction to This Specific Extract: If a patient has previously experienced near-fatal anaphylaxis from Pleospora Herbarum, the risks of continuing usually outweigh the benefits.
• Inability to Communicate: Patients who cannot report symptoms (e.g., very young infants or those with severe cognitive impairment) are at risk because early signs of a reaction may be missed.

• Pregnancy: While not an absolute contraindication for those already on a stable maintenance dose, starting a new build-up phase of Pleospora Herbarum during pregnancy is generally avoided due to the risk of maternal anaphylaxis causing fetal hypoxia.
• Autoimmune Disorders: Patients with active systemic lupus erythematosus (SLE) or rheumatoid arthritis may have unpredictable immune responses to immunotherapy.
• Malignancy: Patients undergoing active chemotherapy should generally defer immunotherapy.

Patients allergic to Pleospora Herbarum often show cross-sensitivity to other molds in the Pleosporaceae family, such as Alternaria alternata and Stemphylium. A positive test for one often implies a sensitivity to the others, and the cumulative 'allergen load' must be considered when dosing.

> Important: Your healthcare provider will evaluate your complete medical history, including your lung function and heart health, before prescribing Pleospora Herbarum.

Pleospora Herbarum is classified as FDA Pregnancy Category C. This means that animal reproduction studies have not been conducted, and it is not known whether the extract can cause fetal harm. The primary risk to the fetus is not the extract itself, but the potential for the mother to experience anaphylaxis, which can lead to a sudden drop in blood pressure and uterine blood flow, causing fetal distress or death. Most allergists will continue a woman on her 'maintenance' dose if she becomes pregnant, but they will not increase the dose or start the therapy from scratch during the pregnancy.

It is not known if the antigenic components of Pleospora Herbarum are excreted in human milk. However, because these are large proteins that are likely broken down in the mother's lymphatic system and would be further digested in the infant's stomach, the risk to a nursing infant is considered extremely low. Breastfeeding is generally considered safe during Pleospora Herbarum immunotherapy.

Pleospora Herbarum is approved for use in children who have a clear clinical history of mold allergy. The safety profile in children is similar to that in adults, though children may have more difficulty communicating the early 'itchy throat' or 'chest tightness' symptoms of a reaction. Close observation by a pediatric allergist is mandatory. There is no evidence that fungal immunotherapy stunts growth or affects development.

In patients over 65, the decision to use Pleospora Herbarum must be individualized. The risk of polypharmacy (taking many medications) is higher, increasing the chance of a drug interaction (especially with beta-blockers). Additionally, the 'wheal and flare' response on the skin may be diminished in elderly patients, leading to potentially less accurate diagnostic results.

There are no specific guidelines for renal impairment. Because the extract is a biological protein, it does not accumulate in the blood in the same way a chemical drug like gabapentin or digoxin would. No dose adjustment is typically needed for patients with chronic kidney disease (CKD).

Similarly, hepatic impairment does not affect the safety or efficacy of Pleospora Herbarum. The liver is not the primary site of clearance for injected allergenic proteins.

> Important: Special populations, particularly pregnant women and the elderly, require individualized medical assessment and a cautious approach to dosing.

Pleospora Herbarum acts as an exogenous antigen that interacts with the Type I hypersensitivity pathway. Upon injection, the fungal proteins are processed by antigen-presenting cells (APCs), such as macrophages and dendritic cells. In an allergic individual, this normally triggers a Th2 response. Immunotherapy with Pleospora Herbarum aims to 're-train' the immune system to produce IL-10 and TGF-beta, cytokines that promote the development of T-regulatory cells. These cells then suppress the allergic cascade and encourage B-cells to switch production from IgE to IgG4.

The pharmacodynamic effect is delayed. While the 'insult' to the immune system happens at the time of injection, the 'effect' (reduction in allergy symptoms) usually takes 3 to 6 months to become noticeable. The duration of the effect can be long-lasting; many patients who complete a 5-year course of Pleospora Herbarum immunotherapy remain symptom-free for years after stopping.

| Parameter | Value |

|---|---|

| Bioavailability | N/A (Subcutaneous Injection) |

| Protein Binding | Primarily binds to specific IgE and IgG antibodies |

| Half-life | Varies (Antigens are cleared within hours to days) |

| Tmax | 15-30 minutes for local skin reaction |

| Metabolism | Proteolysis by tissue enzymes |

| Excretion | Renal/Biliary (as metabolites) |

• Molecular Formula: N/A (Complex biological mixture)
• Molecular Weight: Ranges from 10 kDa to over 100 kDa (for various fungal proteins)
• Solubility: Soluble in aqueous buffers and saline solutions.
• Structure: A mixture of proteins, glycoproteins (Alt a 1-like homologs), and polysaccharides derived from Pleospora herbarum mycelia.

Pleospora Herbarum is a Non-Standardized Fungal Allergenic Extract. It is grouped with other fungal extracts such as Alternaria, Cladosporium, and Aspergillus. It is distinct from standardized extracts like Dermatophagoides (dust mite) or Phleum pratense (Timothy grass).